

HR 985

FAST Generics Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 5, 2019

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Feb 5, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/985>

Sponsor

Name: Rep. Welch, Peter [D-VT-At Large]

Party: Democratic • **State:** VT • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cicilline, David N. [D-RI-1]	D · RI		Feb 5, 2019
Rep. McKinley, David B. [R-WV-1]	R · WV		Feb 5, 2019
Rep. Cartwright, Matt [D-PA-8]	D · PA		Mar 11, 2019
Rep. Slotkin, Elissa [D-MI-8]	D · MI		May 20, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Feb 5, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 5, 2019)

Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019

This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.

Actions Timeline

- **Feb 5, 2019:** Introduced in House
- **Feb 5, 2019:** Referred to the House Committee on Energy and Commerce.